Presenter: Dr. Ken Chapman, University of Toronto, ON
Moderator: Dr. Robert Sandhaus, National Jewish Health, Denver, CO

Pulmonary disease caused by alpha-1 antitrypsin deficiency is typically diagnosed late or missed completely.  This presentation will review practical strategies for screening and for confirming the diagnosis.  Appropriate use of augmentation therapy will be discussed as well as the evidence behind current recommendations.  Comprehensive care issues such as family screening, patient education and screening for liver disease will be reviewed.

Learning objectives
At the end of the presentation, attendees will be able to:

  • Understand the pathogenesis of Alpha-1 Antitrypsin Deficiency (AATD) as a genetic risk factor for COPD;
  • Summarize the latest evidence for use of augmentation therapy for AATD; and
  • Efficiently screen for AATD using Canadian tools and resources.

CanMEDs roles addressed:

Health Advocate


This session is co-developed by the Canadian Thoracic Society and Grifols and is planned to achieve scientific integrity, objectivity and balance.